Innate Immune Responses to Chimpanzee Adenovirus Vector 155 Vaccination in Mice and Monkeys

被引:26
作者
Collignon, Catherine [1 ]
Bol, Vanesa [1 ]
Chalon, Aurelie [1 ]
Surendran, Naveen [2 ,4 ]
Morel, Sandra [1 ]
van den Berg, Robert A. [2 ]
Capone, Stefania [3 ]
Bechtold, Viviane [1 ]
Temmerman, Stephane T. [1 ]
机构
[1] GSK, Preclin R&D, Rixensart, Belgium
[2] GSK, Discovery Performance Unit, Rockville, MD USA
[3] ReiThera Srl, Preclin R&D, Rome, Italy
[4] Pfizer Vaccines R&D, Bacterial Vaccines & Technol, Pearl River, NY USA
来源
FRONTIERS IN IMMUNOLOGY | 2020年 / 11卷
关键词
innate immunity; chimpanzee adenovirus; adenovirus vector; vaccine; mice; monkeys; SKELETAL-MUSCLE; DENDRITIC CELLS; OBSERVER-BLIND; EBOLA VACCINE; SEROTYPE; 5; IMMUNOGENICITY; REACTOGENICITY; ACTIVATION; CHALLENGES; MIGRATION;
D O I
10.3389/fimmu.2020.579872
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Replication-deficient chimpanzee adenovirus (ChAd) vectors represent an attractive vaccine platform and are thus employed as vaccine candidates against several infectious diseases. Since inducing effective immunity depends on the interplay between innate and adaptive immunity, a deeper understanding of innate immune responses elicited by intramuscularly injected ChAd vectors in tissues can advance the platform's development. Using different candidate vaccines based on the Group C ChAd type 155 (ChAd155) vector, we characterized early immune responses in injected muscles and draining lymph nodes (dLNs) from mice, and complemented these analyses by evaluating cytokine responses and gene expression patterns in peripheral blood from ChAd155-injected macaques. In mice, vector DNA levels gradually decreased post-immunization, but local transgene mRNA expression exhibited two transient peaks [at 6 h and Day (D)5], which were most obvious in dLNs. This dynamic pattern was mirrored by the innate responses in tissues, which developed as early as 1-3 h (cytokines/chemokines) or D1 (immune cells) post-vaccination. They were characterized by a CCL2- and CXCL9/10-dominated chemokine profile, peaking at 6 h (with CXCL10/CCL2 signals also detectable in serum) and D7, and clear immune-cell infiltration peaks at D1/D2 and D6/D7. Experiments with a green fluorescent protein-expressing ChAd155 vector revealed infiltrating hematopoietic cell subsets at the injection site. Cell infiltrates comprised mostly monocytes in muscles, and NK cells, T cells, dendritic cells, monocytes, and B cells in dLNs. Similar bimodal dynamics were observed in whole-blood gene signatures in macaques: most of the 17 enriched immune/innate signaling pathways were significantly upregulated at D1 and D7 and downregulated at D3, and clustering analysis revealed stronger similarities between D1 and D7 signatures versus the D3 signature. Serum cytokine responses (CXCL10, IL1Ra, and low-level IFN-alpha) in macaques were predominantly observed at D1. Altogether, the early immune responses exhibited bimodal kinetics with transient peaks at D1/D2 and D6/D7, mostly with an IFN-associated signature, and these features were remarkably consistent across most analyzed parameters in murine tissues and macaque blood. These compelling observations reveal a novel aspect of the dynamics of innate immunity induced by ChAd155-vectored vaccines, and contribute to ongoing research to better understand how adenovectors can promote vaccine-induced immunity.
引用
收藏
页数:16
相关论文
共 47 条
  • [31] Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling
    Quinn, Kylie M.
    Zak, Daniel E.
    Costa, Andreia
    Yamamoto, Ayako
    Kastenmuller, Kathrin
    Hill, Brenna J.
    Lynn, Geoffrey M.
    Darrah, Patricia A.
    Lindsay, Ross W. B.
    Wang, Lingshu
    Cheng, Cheng
    Nicosia, Alfredo
    Folgori, Antonella
    Colloca, Stefano
    Cortese, Riccardo
    Gostick, Emma
    Price, David A.
    Gall, Jason G. D.
    Roederer, Mario
    Aderem, Alan
    Seder, Robert A.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (03) : 1129 - 1146
  • [32] Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization
    Quinn, Kylie M.
    Da Costa, Andreia
    Yamamoto, Ayako
    Berry, Dana
    Lindsay, Ross W. B.
    Darrah, Patricia A.
    Wang, Lingshu
    Cheng, Cheng
    Kong, Wing-Pui
    Gall, Jason G. D.
    Nicosia, Alfredo
    Folgori, Antonella
    Colloca, Stefano
    Cortese, Riccardo
    Gostick, Emma
    Price, David A.
    Gomez, Carmen E.
    Esteban, Mariano
    Wyatt, Linda S.
    Moss, Bernard
    Morgan, Cecilia
    Roederer, Mario
    Bailer, Robert T.
    Nabel, Gary J.
    Koup, Richard A.
    Seder, Robert A.
    [J]. JOURNAL OF IMMUNOLOGY, 2013, 190 (06) : 2720 - 2735
  • [33] Multiple Innate Immune Pathways Contribute to the Immunogenicity of Recombinant Adenovirus Vaccine Vectors
    Rhee, Elizabeth G.
    Blattman, Joseph N.
    Kasturi, Sudhir P.
    Kelley, R. Phelps
    Kaufman, David R.
    Lynch, Diana M.
    La Porte, Annalena
    Simmons, Nathaniel L.
    Clark, Sarah L.
    Pulendran, Bali
    Greenberg, Philip D.
    Barouch, Dan H.
    [J]. JOURNAL OF VIROLOGY, 2011, 85 (01) : 315 - 323
  • [34] Viral vector and route of administration determine the ILC and DC profiles responsible for downstream vaccine-specific immune outcomes
    Roy, S.
    Jaeson, M., I
    Li, Z.
    Mahboob, S.
    Jackson, R. J.
    Grubor-Bauk, B.
    Wijesundara, D. K.
    Gowans, E. J.
    Ranasinghe, C.
    [J]. VACCINE, 2019, 37 (10) : 1266 - 1276
  • [35] TNFα and IFNγ induced by innate anti-adenoviral immune responses inhibit adenovirus-mediated transgene expression
    Sung, RS
    Qin, LH
    Bromberg, JS
    [J]. MOLECULAR THERAPY, 2001, 3 (05) : 757 - 767
  • [36] A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory
    Swadling, Leo
    Capone, Stefania
    Antrobus, Richard D.
    Brown, Anthony
    Richardson, Rachel
    Newell, Evan W.
    Halliday, John
    Kelly, Christabel
    Bowen, Dan
    Fergusson, Joannah
    Kurioka, Ayako
    Ammendola, Virginia
    Del Sorbo, Mariarosaria
    Grazioli, Fabiana
    Esposito, Maria Luisa
    Siani, Loredana
    Traboni, Cinzia
    Hill, Adrian
    Colloca, Stefano
    Davis, Mark
    Nicosia, Alfredo
    Cortese, Riccardo
    Folgori, Antonella
    Klenerman, Paul
    Barnes, Eleanor
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (261)
  • [37] Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial
    Tapia, Milagritos D.
    Sow, Samba O.
    Ndiaye, Birahim P.
    Mbaye, Khardiata D.
    Thiongane, Aliou
    Ndour, Cheikh T.
    Mboup, Souleymane
    Ake, Julie A.
    Keshinro, Babajide
    Akintunde, Gideon A.
    Kinge, Thompson N.
    Vernet, Guy
    Bigna, Jean Joel
    Oguche, Stephen
    Koram, Kwadwo A.
    Asante, Kwaku P.
    Hogrefe, Wayne R.
    Guenther, Stephan
    Naficy, Abdi
    De Ryck, Iris
    Debois, Muriel
    Bourguignon, Patricia
    Jongert, Erik
    Ballou, William R.
    Koutsoukos, Marguerite
    Roman, Francois
    [J]. LANCET INFECTIOUS DISEASES, 2020, 20 (06) : 707 - 718
  • [38] Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial
    Tapia, Milagritos D.
    Sow, Samba O.
    Mbaye, Khardiata D.
    Thiongane, Aliou
    Ndiaye, Birahim P.
    Ndour, Cheikh T.
    Mboup, Souleymane
    Keshinro, Babajide
    Kinge, Thompson N.
    Vernet, Guy
    Bigna, Jean Joel
    Oguche, Stephen
    Koram, Kwadwo A.
    Asante, Kwaku P.
    Gobert, Patrice
    Hogrefe, Wayne R.
    De Ryck, Iris
    Debois, Muriel
    Bourguignon, Patricia
    Jongert, Erik
    Ballou, William R.
    Koutsoukos, Marguerite
    Roman, Francois
    [J]. LANCET INFECTIOUS DISEASES, 2020, 20 (06) : 719 - 730
  • [39] Chimpanzee-origin adenovirus vectors as vaccine carriers
    Tatsis, N
    Tesema, L
    Robinson, ER
    Giles-Davis, W
    McCoy, K
    Gao, GP
    Wilson, JM
    Ertl, HCJ
    [J]. GENE THERAPY, 2006, 13 (05) : 421 - 429
  • [40] Vaccination with Adenovirus Serotypes 35, 26, and 48 Elicits Higher Levels of Innate Cytokine Responses than Adenovirus Serotype 5 in Rhesus Monkeys
    Teigler, Jeffrey E.
    Iampietro, M. Justin
    Barouch, Dan H.
    [J]. JOURNAL OF VIROLOGY, 2012, 86 (18) : 9590 - 9598